Sphera Funds Management’s BioLineRX BLRX Stock Holding History

Sphera Funds Management’s Portfolio BLRX Stock Details BLRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q2	–	Sell	-322	Closed	-$408K	–	137
2015 Q1	$408K	Buy	+322	New	+$396K	0.04%	143
2014 Q4	–	Sell	-322	Closed	-$298K	–	133
2014 Q3	$298K	Sell	322 -678	-68%	-$728K	0.04%	120
2014 Q2	$1.25M	Hold	1,000	–	–	0.31%	71
2014 Q1	$1.34M	Buy	+1,000	New	+$1.64M	0.31%	70

Other funds holding BLRX

Senvest Management New York $3.01B AUM 35.7% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

NCCM

Nine Chapters Capital Management Short Hills, New Jersey $45.4M AUM 14.43% 1-Year Est. Return

BCA

Benchmark Capital Advisors New York $101M AUM 0.8% 1-Year Est. Return

Sphera Funds Management's BLRX Position: Q2 2015 in Review

Sphera Funds Management sold out of BioLineRX (BLRX) in Q2 2015, closing a stake of 322 shares — an estimated $408K sold.

Sphera Funds Management first reported a position in BLRX in Q1 2014 and held it in 4 quarters. The position peaked at $1.34M in Q1 2014. 20 funds tracked by Wall St. Rank hold BLRX as of Q2 2015.

Sphera Funds Management reported no remaining BioLineRX position as of Q2 2015 after selling out during the quarter.
Sphera Funds Management sold 322 BioLineRX shares in Q2 2015, an estimated $408K.
Sphera Funds Management first reported a position in BioLineRX in Q1 2014 and held it in 4 quarters.
Sphera Funds Management's BioLineRX position peaked at $1.34M in Q1 2014.
20 funds tracked by Wall St. Rank held BioLineRX as of Q2 2015.

Based on Sphera Funds Management's 13F filing for Q2 2015, filed 6 Aug 2015.